|
1.
|
|
11 p, 1.2 MB |
Correlation of recist, computed tomography morphological response, and pathological regression in hepatic metastasis secondary to colorectal cancer : The avamet study
/
Vera, Ruth (Instituto de investigaciones Sanitarias de Navarra (IdISNA)) ;
Gómez, María Luisa (Complejo Hospitalario de Navarra) ;
Ayuso Colella, Juan Ramón (Hospital Clínic i Provincial de Barcelona) ;
Figueras, Joan (Hospital Universitari de Girona Doctor Josep Trueta) ;
García-Alfonso, Pilar (Hospital General Universitario Gregorio Marañón) ;
Martínez, Virginia (Hospital Universitario La Paz (Madrid)) ;
Lacasta, Adelaida (Hospital de Donostia (Sant Sebastià, País Basc)) ;
Ruiz-casado, Ana (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Safont, María José (Hospital General Universitario de Valencia) ;
Aparicio Urtasun, Jorge (Hospital Universitari i Politècnic La Fe (València)) ;
Campos, Juan Manuel (Hospital Arnau de Vilanova (València)) ;
Cámara, Juan Carlos (Hospital Universitario Fundación Alcorcón) ;
Martín-Richard, Marta (Institut d'Investigació Biomèdica Sant Pau) ;
Montagut Viladot, Clara (Hospital del Mar (Barcelona, Catalunya)) ;
Pericay, Carles (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Vieitez, Jose María (Hospital Universitario Central de Asturias) ;
Falcó, Esther (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ;
Jorge, Mónica (Hospital Xeral Cíes) ;
Marín, Miguel (Hospital Clínico Universitario de la Arrixaca) ;
Salgado, Mercedes (Complejo Hospitalario de Ourense) ;
Viúdez, Antonio (Instituto de investigaciones Sanitarias de Navarra (IdISNA)) ;
Universitat Autònoma de Barcelona
The prospective phase IV AVAMET study was undertaken to correlate response evaluation criteria in solid tumors (RECIST)-defined response rates with computed tomography-based morphological criteria (CTMC) and pathological response after liver resection of colorectal cancer metastases. [...]
2020 -  10.3390/cancers12082259
Cancers, Vol. 12 Núm. 8 (august 2020) , p. 1-12
|
|
|
2.
|
|
9 p, 267.6 KB |
VITAL phase 2 study : Upfront 5-fluorouracil, mitomycin-C, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal (GEMCAD 09-02)
/
Feliu, Jaime (Hospital Universitario La Paz (Madrid)) ;
Garcia-Carbonero, Rocio (Hospital Universitario 12 de Octubre (Madrid)) ;
Capdevila, J (Vall d'Hebron Institut d'Oncologia) ;
Guasch, Inmaculada (Hospital Althaia Assistencial de Manresa) ;
Alonso-Orduña, Vícente (Hospital Universitario Miguel Servet (Saragossa)) ;
López-López, Carlos A. (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
García-Alfonso, Pilar (Hospital General Universitario Gregorio Marañón) ;
Castañón, Carmen (Hospital Virgen Blanca) ;
Sevilla, Isabel Ñíguez (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Cerezo, Laura (Hospital Universitario de la Princesa (Madrid)) ;
Conill, Carlos (Universitat de Barcelona) ;
Quintana Ángel, Begoña (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Sánchez, María E. (Hospital Universitario La Paz (Madrid)) ;
Ghanem, Ismael (Hospital Universitario La Paz (Madrid)) ;
Martín-Richard, Marta (Institut d'Investigació Biomèdica Sant Pau) ;
Lopez-Gomez, Miriam (Hospital Universitario Infanta Sofía (San Sebastián de los Reyes)) ;
León, Ana Isabel (Hospital Universitario Fundacion Jimenez Diaz) ;
Caro, Monica (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Fernandez, Teresa López (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ;
Maurel, Joan (Universitat de Barcelona) ;
Universitat Autònoma de Barcelona
VITAL, a phase II single-arm study, aimed to evaluate efficacy and safety of panitumumab addition to 5-fluorouracil (5-FU), mitomycin-C (MMC) and radiotherapy (RT) in patients with localized squamous cell carcinoma of the anal canal (SCCAC). [...]
2020 - 10.1002/cam4.2722
Cancer Medicine, Vol. 9 Núm. 3 (january 2020) , p. 1008-1016
|
|
|
3.
|
|
10 p, 1.2 MB |
A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial)
/
Argilés Martínez, Guillem ;
Mulet, N. (Memorial Sloan Kettering Cancer Center) ;
Valladares-Ayerbes, M. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Viéitez, J.M. (Hospital Universitario Central de Asturias) ;
Grávalos, Cristina (Hospital Universitario 12 de Octubre (Madrid)) ;
García-Alfonso, P. (H. Gregorio Marañón) ;
Santos, C. (ICO. H. Duran i Reynals) ;
Tobeña, M. (Institut d'Investigació Biomèdica Sant Pau) ;
García Paredes, B. (H. Universitario Clínico San Carlos) ;
Benavides Orgaz, Manuel (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Cano, M.T. (H. Universitario Reina Sofía) ;
Loupakis, F. (IOV (Istituto oncologico Veneto)) ;
Rodríguez-Garrote, M. (Instituto Ramón y Cajal de Investigación Sanitaria (Madrid)) ;
Rivera, F. (Instituto de Investigación Marqués de Valdecilla) ;
Goldberg, R.M. (West Virgina University Cancer Institute) ;
Cremolini, Chiara (A. O. Universitaria Pisana) ;
Bennouna, J. (CHU-Nante) ;
Ciardiello, Fortunato ;
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ;
Aranda Aguilar, Enrique (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ;
Tabernero, J. (Memorial Sloan Kettering Cancer Center) ;
Falcone, A. (Gustave Roussy) ;
Goldberg, R. ;
Argilés, None (Memorial Sloan Kettering Cancer Center) ;
Tabernero, J. (Memorial Sloan Kettering Cancer Center) ;
Mulet, N. (Memorial Sloan Kettering Cancer Center) ;
Limón, M.L. (H. Virgen del Rocío) ;
Valladares, M. (H. Virgen del Rocío) ;
Jiménez, P. (H. Universitario Central de Asturias) ;
Vieitez, J.M. (H. Universitario Central de Asturias) ;
Grávalos, C. (H. 12 de Octubre) ;
García-Alfonso, P. (H. Gregorio Marañón) ;
Santos, C. (ICO. H. Duran i Reynals) ;
Páez, David (Institut d'Investigació Biomèdica Sant Pau) ;
Sastre Valera, Javier (H. Universitario Clínico San Carlos) ;
García Paredes, B. (H. Universitario Clínico San Carlos) ;
Benavides Orgaz, Manuel (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Aranda Aguilar, Enrique (H. Universitario Reina Sofía) ;
Cano, M.T. (H. Universitario Reina Sofía) ;
Loupakis, F. (IOV (Istituto oncologico Veneto)) ;
Rguez Garrote, M. (H. Ramón y Cajal) ;
Guillén, C. (H. Ramón y Cajal) ;
Rivera, M.F. (H. Marqués de Valdecilla) ;
Safont, J. (H. General Universitario) ;
Hiret, S. (Institut de Cancérologie de l'Ouest) ;
Bennouna, J. (CHU-Nante) ;
Pannier, D. (Centre Oscar Lambret) ;
Malka, D. (Gustave Roussy) ;
Falcone, A. (Gustave Roussy) ;
Cremolini, Chiara (A. O. Universitaria Pisana) ;
Universitat Autònoma de Barcelona
Purpose: The purpose of this article is to evaluate the safety of two regorafenib dose-escalation approaches in refractory metastatic colorectal cancer (mCRC) patients. Patients and methods: Patients with mCRC and progression during or within 3 months following their last standard chemotherapy regimen were randomised to receive the approved dose of regorafenib of 160 mg QD (arm A) or 120 mg QD (arm B) administered as 3 weeks of treatment followed by 1 week off, or 160 mg QD 1 week on/1 week off (arm C). [...]
2022 - 10.1016/j.ejca.2022.09.037
European journal of cancer, Vol. 177 (december 2022) , p. 154-163
|
|
|
4.
|
|
12 p, 926.4 KB |
Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines
/
García-Alfonso, Pilar (Hospital General Universitario Gregorio Marañón) ;
Saiz-Rodríguez, M. (Hospital Universitario de Burgos) ;
Mondéjar, R. (Hospital Universitario de la Princesa (Madrid)) ;
Salazar, Juliana (Institut d'Investigació Biomèdica Sant Pau) ;
Páez, David (Institut d'Investigació Biomèdica Sant Pau) ;
Borobia, Alberto M (Hospital Universitario La Paz (Madrid)) ;
Safont, M. J. (Universitat de València) ;
García-García, Irene (Hospital 12 de Octubre (Madrid)) ;
Colomer, Ramon (Hospital Universitario de la Princesa (Madrid)) ;
García-González, Xandra (Hospital General Universitario Gregorio Marañón) ;
Herrero Cervera, María José (Universitat de València) ;
López-Fernández, L. A. (Hospital General Universitario Gregorio Marañón) ;
Abad-Santos, Francisco (Hospital Universitario de la Princesa (Madrid)) ;
Universitat Autònoma de Barcelona
5-Fluorouracil (5-FU) and oral fluoropyrimidines, such as capecitabine, are widely used in the treatment of cancer, especially gastrointestinal tumors and breast cancer, but their administration can produce serious and even lethal toxicity. [...]
2021 - 10.1007/s12094-021-02708-4
Clinical & Translational Oncology, Vol. 24 (november 2021) , p. 483-494
|
|
|
5.
|
|
9 p, 1.6 MB |
Description of the genetic variants identified in a cohort of patients diagnosed with localized anal squamous cell carcinoma and treated with panitumumab
/
Trilla-Fuertes, Lucía (Biomedica Molecular Medicine (Madrid)) ;
Gámez-Pozo, Angelo (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ;
Maurel, Joan (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
García-Carbonero, Rocío (Instituto de Investigación Sanitaria Hospital 12 de Octubre (i+12)) ;
Capdevila Castillón, Jaume (Vall d'Hebron Institut d'Oncologia) ;
G-Pastrián, Laura (Hospital Universitario La Paz (Madrid)) ;
Mendiola, Marta (Centro de Investigación Biomédica en Red de Cáncer) ;
Peña, Cristina (Hospital Universitario La Paz (Madrid)) ;
López-Vacas, Rocío (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ;
Cuatrecasas, Miriam (Hospital Clínic i Provincial de Barcelona) ;
García-Alfonso, Pilar (Hospital General Universitario Gregorio Marañón) ;
Ramos-Ruiz, Ricardo (Genomics Unit Cantoblanco) ;
Llorens, Carlos (Biotechvana SL (Madrid)) ;
Ghanem, Ismael (Hospital Universitario La Paz (Madrid)) ;
Conill, Carles (Hospital Clínic i Provincial de Barcelona) ;
Heredia Soto, Victoria (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ;
Campos-Barros, Ángel (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ;
Fresno Vara, Juan Ángel (Centro de Investigación Biomédica en Red de Cáncer) ;
Feliu, Jaime (Universidad Autónoma de Madrid) ;
Universitat Autònoma de Barcelona
Squamous cell carcinoma is the most frequent histologic type of anal carcinoma. The standard of care since the 1970s has been a combination of 5-fluorouracil, mitomycin C, and radiotherapy. This treatment is very effective in T1/T2 tumors (achieving complete regression in 80-90% of tumors). [...]
2021 - 10.1038/s41598-021-86966-w
Scientific reports, Vol. 11 (april 2021)
|
|
|
6.
|
|
9 p, 1.3 MB |
Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies : exploratory analyses of the RAISE trial and validation in an electronic medical record data set
/
Grothey, Axel (Mayo Clinic) ;
Yoshino, Takayuki (National Cancer Center Hospital East) ;
Bodoky, Gyorgy (St László Hospital (Hongria)) ;
Ciuleanu, Tudor Eliade (The Oncology Institute Prof Dr Ion Chiricută and Iuliu Hațieganu University of Medicine and Pharmacy) ;
García-Carbonero, Rocío (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
García-Alfonso, Pilar (Hospital General Universitario Gregorio Marañón) ;
Van Cutsem, Eric (University Hospitals Leuven (Bèlgica)) ;
Muro, Kei (Aichi Cancer Center Hospital) ;
Mytelka, Daniel S. (Formerly of Eli Lilly and Company) ;
Li, Li (Eli Lilly and Company) ;
Lipkovich, Olga (Eli Lilly and Company) ;
Hsu, Yanzhi (Eli Lilly and Company) ;
Sashegyi, Andreas (Eli Lilly and Company) ;
Ferry, David (Eli Lilly and Company) ;
Nasroulah, Federico (Eli Lilly Argentina) ;
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
In the RAISE trial, ramucirumab+leucovorin/fluorouracil/irinotecan (FOLFIRI) improved the median overall survival (mOS) of patients with previously treated metastatic colorectal cancer versus patients treated with placebo+FOLFIRI but had a higher incidence of neutropaenia, leading to more chemotherapy dose modifications and discontinuations. [...]
2018 - 10.1136/esmoopen-2018-000347
ESMO open, Vol. 3 (april 2018)
|
|
|
7.
|
|
16 p, 1003.6 KB |
Update of the recommendations for the determination of biomarkers in colorectal carcinoma : National Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology
/
García-Alfonso, Pilar (Hospital General Universitario Gregorio Marañón) ;
García-Carbonero, Rocío (Hospital Universitario 12 de Octubre (Madrid)) ;
García-Foncillas, Jesús (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz) ;
Pérez-Segura, Pedro (Hospital Clínico San Carlos (Madrid)) ;
Salazar, R. (Centro de Investigación Biomédica en Red de Cáncer) ;
Vera, Ruth (Complejo Hospitalario de Navarra) ;
Ramón y Cajal, S. (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Hernández-Losa, J. (Hospital Universitari Vall d'Hebron) ;
Landolfi, Stefania (Vall d'Hebron Institut d'Oncologia) ;
Musulén, Eva (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Cuatrecasas, Miriam (Hospital Clínic i Provincial de Barcelona) ;
Navarro, S. (Hospital Clínic Universitari (València)) ;
Universitat Autònoma de Barcelona
In this update of the consensus of the Spanish Society of Medical Oncology (Sociedad Española de Oncología Médica-SEOM) and the Spanish Society of Pathology (Sociedad Española de Anatomía Patológica-SEAP), advances in the analysis of biomarkers in advanced colorectal cancer (CRC) as well as susceptibility markers of hereditary CRC and molecular biomarkers of localized CRC are reviewed. [...]
2020 - 10.1007/s12094-020-02357-z
Clinical & Translational Oncology, Vol. 22 (may 2020) , p. 1976-1991
|
|
|
8.
|
|
8 p, 712.6 KB |
Biomarker analysis beyond angiogenesis : RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study
/
Yoshino, Takayuki (National Cancer Center Hospital East, Kashiwa, Japan) ;
Portnoy, D. C. (The West Clinic, Memphis, USA) ;
Obermannová, R. (Masarykuv Onkologicky Ustav, Brno, Czech Republic) ;
Bodoky, G. (St László Hospital (Hongria)) ;
Prausová, J. (Fakultni Nemocnice v MOTOLE, Prague, Czech Republic) ;
García-Carbonero, Rocío (Hospital Universitario 12 de Octubre (Madrid)) ;
Ciuleanu, Tudor Eliade (Institutul Oncologic Ion Chiricuta and UMF Iuliu Hatieganu, Cluj-Napoca, Romania) ;
García-Alfonso, Pilar (Hospital General Universitario Gregorio Marañón) ;
Cohn, A. L. (Rocky Mountain Cancer Center, LLP, Denver, USA) ;
Van Cutsem, E. (University Hospitals Gasthuisberg (Leuven, Bélgica)) ;
Yamazaki, K. (Shizuoka Cancer Center, Shizuoka, Japan) ;
Lonardi, Sara (Istituto Oncologico Veneto-IRCCS, Padova, Italy) ;
Muro, K. (Aichi Cancer Center Hospital) ;
Kim, T. W. (Asan Medical Center, University of Ulsan, Seoul, Republic of Korea) ;
Yamaguchi, K. (The Cancer Institute Hospital of JFCR, Tokyo, Japan) ;
Grothey, A. (Mayo Clinic, Phoenix, USA) ;
O'Connor, J. (Instituto Alexander Fleming (Buenos Aires, Argentina)) ;
Taieb, Julien (Sorbonne Paris Cité, Paris Descartes University, Georges Pompidou European Hospital, Paris, France) ;
Wijayawardana, S. R. (Eli Lilly and Company, Indianapolis, USA) ;
Hozak, Rebecca R (Eli Lilly and Company, Indianapolis, USA) ;
Nasroulah, F. (Eli Lilly and Company, Buenos Aires, Argentina) ;
Tabernero, Josep (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Vall d'Hebron Institut d'Oncologia
: Second-line treatment with ramucirumab+FOLFIRI improved overall survival (OS) versus placebo+FOLFIRI for patients with metastatic colorectal carcinoma (CRC) [hazard ratio (HR)=0. 84, 95% CI 0. 73-0. [...]
2018 - 10.1093/annonc/mdy461
Annals of oncology, Vol. 30 (october 2018) , p. 124-131
|
|
|
9.
|
|
8 p, 1.4 MB |
Comprehensive Characterization of the Mutational Landscape in Localized Anal Squamous Cell Carcinoma
/
Trilla-Fuertes, Lucía (Biomedica Molecular Medicine (Madrid)) ;
Ghanem, Ismael (Hospital Universitario La Paz (Madrid)) ;
Maurel, Joan (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
G-Pastrián, Laura (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ;
Mendiola, Marta (Centro de Investigación Biomédica en Red de Cáncer) ;
Peña, Cristina (Hospital Universitario La Paz (Madrid)) ;
López-Vacas, Rocío (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ;
Prado-Vázquez, Guillermo (Biomedica Molecular Medicine (Madrid)) ;
López-Camacho, Elena (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ;
Zapater-Moros, Andrea (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ;
Heredia Soto, Victoria (Hospital Universitario La Paz (Madrid)) ;
Cuatrecasas, Miriam (Hospital Clínic i Provincial de Barcelona) ;
García-Alfonso, Pilar (Hospital General Universitario Gregorio Marañón) ;
Capdevila Castillón, Jaume (Vall d'Hebron Institut d'Oncologia) ;
Conill, Carles (Hospital Clínic i Provincial de Barcelona) ;
García-Carbonero, Rocío (Hospital Universitario 12 de Octubre (Madrid)) ;
Heath, Karen E. (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ;
Ramos-Ruiz, Ricardo (Genomics Unit Cantoblanco, Parque Científico de Madrid, C/ Faraday 7, 28049, Madrid, Spain) ;
Llorens, Carlos (Biotechvana SL, Parque Científico de Madrid, C/ Faraday 7, 28049, Madrid, Spain) ;
Campos-Barros, Ángel (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ;
Gámez-Pozo, Angelo (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ;
Feliu, Jaime (Universidad Autónoma de Madrid) ;
Vara, Juan Ángel Fresno (Instituto de Investigación Sanitaria del Hospital Universitario La Paz)
Anal squamous cell carcinoma (ASCC) is a rare neoplasm. Chemoradiotherapy is the standard of care, with no therapeutic advances achieved over the past three decades. Thus, a deeper molecular characterization of this disease is still necessary. [...]
2020 - 10.1016/j.tranon.2020.100778
Translational Oncology, Vol. 13 (may 2020)
|
|
|
10.
|
|
8 p, 412.5 KB |
Subgroup analysis in RAISE : a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression
/
Obermannová, R. (Masaryk Memorial Cancer Institute (Brno, República Txeca)) ;
Van Cutsem, E. (University Hospitals Leuven (Bèlgica)) ;
Yoshino, Takayuki (National Cancer Center Hospital East (Japan)) ;
Bodoky, G. (St László Hospital (Hongria)) ;
Prausová, J. (Charles University. Onocology Clinic (Czech Republic)) ;
García-Carbonero, Rocío (Hospital Universitario 12 de Octubre (Madrid)) ;
Ciuleanu, Tudor Eliade (Institutul Oncologic Ion Chiricuta and UMF (Romania)) ;
Garcia Alfonso, P. (Hospital General Universitario Gregorio Marañón) ;
Portnoy, D. (The University of Tennessee. Health Science Center (USA)) ;
Cohn, A. L. (Rocky Mountain Cancer Center (USA)) ;
Yamazaki, K. (Shizouka Cancer Center (Japan)) ;
Clingan, P. (Southern Medical Day Care Centre (Australia)) ;
Lonardi, Sara (Istituto Oncologico Veneto-IRCCS (Italy)) ;
Kim, T. W. (University of Ulsan College of Medicine. Asan Medical Center (South Corea)) ;
Yang, L. (Eli Lilly and Company (USA)) ;
Nasroulah, F. (Eli Lilly and Company (República Argentina)) ;
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
The RAISE phase III trial demonstrated ramucirumab + FOLFIRI improved survival compared with placebo + FOLFIRI for second-line metastatic colorectal carcinoma patients previously treated with first-line bevacizumab, oxaliplatin, and a fluoropyrimidine. [...]
2016 - 10.1093/annonc/mdw402
Annals of oncology, Vol. 27, Issue 11 (November 2016) , p. 2082-2090
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
